Neuro-Ophthalmology最新文献_第8页

Neuro-Ophthalmic Literature Review 神经眼科文献综述

IF 0.8

Neuro-Ophthalmology Pub Date : 2021-01-02 DOI: 10.1080/01658107.2021.1877990

D. Bellows, N. Chan, John J. Chen, Hui-Chen Cheng, J. N. Nij Bijvank, M. Vaphiades

{"title":"Neuro-Ophthalmic Literature Review","authors":"D. Bellows, N. Chan, John J. Chen, Hui-Chen Cheng, J. N. Nij Bijvank, M. Vaphiades","doi":"10.1080/01658107.2021.1877990","DOIUrl":"https://doi.org/10.1080/01658107.2021.1877990","url":null,"abstract":"Neuro-Ophthalmic Literature Review David A. Bellows, Noel C.Y. Chan, John J. Chen , Hui-Chen Cheng, Jenny A. Nij Bijvank, and Michael S. Vaphiades New Findings Contradict Previous Credenda Regarding Paediatric Optic Neuritis Pineles SL, Repka MX, Liu GT, Waldman AT, Borchert MS, Khanna S, Heidary G, Graves JS, Shah VS, Kupersmith MJ, Kraker RT. Assessment of paediatric optic neuritis visual acuity outcomes at 6 months. JAMA Ophthalmol. 2020;138(12):1253– 1261. doi:10.1001/jamaophthalmol.2020.4231 This prospective study was the fruit of the joint efforts of the Paediatric Eye Disease Investigator Group and the Neuro-Ophthalmology Research Disease Investigator Consortium at 23 academic and community-based clinical sites. Forty-four children aged 3 to 15 years were entered into the study of which 37 completed the six-month follow-up. Sixteen (36%) of the children presented with bilateral optic neuritis and the remainder were unilateral. Optic disk oedema was seen in 41 eyes (75%) and retinal haemorrhages in two eyes (4%). Magnetic resonance imaging (MRI) revealed optic nerve enhancement in 36 (92%) children and white matter lesions in 23 (52%). Fifteen of the children were tested for NMO antibodies and, of these, only one (7%) tested positive. Thirteen of the enrollees were tested for MOG antibodies and, in this group, seven (54%) tested positive. The mean distance visual acuity of 54 eyes at enrolment was 20/200. Twenty-eight eyes had a visual acuity of less than 20/200 and 16 eyes were less than 20/800. Factors associated with poor visual acuity included younger age, nonWhite and non-Hispanic ethnicity, an associated neurological autoimmune diagnosis (such as ADEM, NMO or MOG), and the presence of brain lesions on MRI. Thirty-seven patients remained in the study at 6 months. Their mean improvement in visual acuity was eight lines on a standard ETDRS chart. Thirtyfour (77%) of the children fell within their agenormal range and two children (4%) had a visual acuity worse than 20/200. These data contradict the standard teachings that most cases of paediatric optic neuritis are bilateral and neurologically isolated. David A. Bellows More AI coming up: Differentiating NGON from GON Yang HK, Kim YJ, Sung JY, Kim DH, Kim KG, Hwang J-M. Efficacy for differentiating nonglaucomatous versus glaucomatous optic neuropathy using deep learning systems. Am J Ophthalmol 2020; 216:140–146. doi:10.1016/j.ajo.2020.03.035 The investigators of this single institute developed an Artificial Intelligence Classification algorithm to differentiate images with normal optic discs, glaucomatous optic neuropathies (GON) and non-glaucomatous optic neuropathies (NGON). Among 3,815 fundus images collected, there were 486 GON images and 446 NGON images where the rest were normal optic disc images. Diagnosis of NGON included compressive optic neuropathy, Leber hereditary optic neuropathy, autosomal dominant optic atrophy, toxic and traumatic optic neuropathy, as well as optic atroph","PeriodicalId":19257,"journal":{"name":"Neuro-Ophthalmology","volume":"79 1","pages":"68 - 73"},"PeriodicalIF":0.8,"publicationDate":"2021-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80908327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuro-Ophthalmic Literature Review 神经眼科文献综述

IF 0.8

Neuro-Ophthalmology Pub Date : 2020-11-01 DOI: 10.1080/01658107.2020.1828705

D. Bellows, N. Chan, John J. Chen, Hui-Chen Cheng, P. Macintosh, J. N. Nij Bijvank, M. Vaphiades

引用次数: 0

List of Reviewers for Volume 44 第44卷的审稿人名单

IF 0.8

Neuro-Ophthalmology Pub Date : 2020-11-01 DOI: 10.1080/01658107.2020.1853482

引用次数: 0

Botulinum neurotoxin for head and neck disorders 肉毒杆菌神经毒素治疗头颈部疾病

IF 0.8

Neuro-Ophthalmology Pub Date : 2020-10-06 DOI: 10.1080/01658107.2020.1823998

D. Weinberg

引用次数: 0

Neuro-Ophthalmic Literature Review 神经眼科文献综述

IF 0.8

Neuro-Ophthalmology Pub Date : 2020-09-02 DOI: 10.1080/01658107.2020.1798699

D. Bellows, N. Chan, John J. Chen, Hui-Chen Cheng, P. Macintosh, J. N. Nij Bijvank, M. Vaphiades

引用次数: 0

Neuro-Ophthalmic Literature Review 神经眼科文献综述

IF 0.8

Neuro-Ophthalmology Pub Date : 2020-07-03 DOI: 10.1080/01658107.2020.1773173

D. Bellows, John J. Chen, Hui-Chen Cheng, P. Macintosh, J. N. Nij Bijvank, M. Vaphiades, K. Weber, S. Wong

{"title":"Neuro-Ophthalmic Literature Review","authors":"D. Bellows, John J. Chen, Hui-Chen Cheng, P. Macintosh, J. N. Nij Bijvank, M. Vaphiades, K. Weber, S. Wong","doi":"10.1080/01658107.2020.1773173","DOIUrl":"https://doi.org/10.1080/01658107.2020.1773173","url":null,"abstract":"Neuro-Ophthalmic Literature Review David A. Bellows, John J. Chen, Hui-Chen Cheng, Peter W. MacIntosh, Jenny A. Nij Bijvank, Michael S. Vaphiades, Konrad P. Weber, and Sui H. Wong Duane Syndrome – Proposal for a new classification system Lee YJ, Lee H-J, Kim S-J. Clinical features of duane retraction syndrome: a new classification. Korean J Ophthalmol. 2020;34(2):158–165. doi: 10.3341/ kjo.2019.0100 This retrospective study is based on the analysis of the medical records of 65 patients with Duane Retraction Syndrome (DRS) who visited the Seoul National University Children’s Hospital between 2010 and 2017. The authors have proposed a new and simplified classification system based solely on the angle of deviation in primary gaze. Patients with an exotropia greater than 3 dioptres were classified as “Exo-Duane,” those with an exotropia or esotropia measuring less than 3 dioptres were labelled “Ortho-Duane” and finally, those with an esotropia exceeding 3 dioptres were classified as “Eso-Duane.” Exo-Duane was found to be the most common presentation (53.8%) while 33.8% were Eso-Duane and 12.3% were Otho-Duane. 56.9% of the patients were male and 43.1% were female with no significant difference in sex proportion between the subclassifications. As documented in previous studies, there was a predominance of left eye involvement (70.8%) followed by the right eye (24.6%) and both eyes (4.6%). In addition to the deviation in primary position the authors report an upshoot of the affected eye in 35.4%, a downshoot in 15.4%, narrowing of the palpebral fissure in 46.2%, and globe retraction in 9.2%. 9.2% of patients also had a hypertropia, predominantly in the Exo-Duane group. The most common refractive error was hyperopia (68.9%) followed by myopia in (26.2%). Comorbidities were found in 10.8% of patients including Goldenhar syndrome, Noonan syndrome and asthma. One patient had a “central nervous system” disease which was not further defined. The authors make the point that the Huber system of classifications is somewhat incommodious for several reasons. The Huber classification is partially based on EMG patterns which are not always feasible to obtain and frequently present with atypical patterns. The Huber classification also relies on subjective and, therefore, inconsistent estimates of abduction or adduction deficits. The authors propose that this new and simplified classification is based on objective findings alone and will enable better communication between practitioners. David A. Bellows Ocular changes in astronauts from spaceflight Macias BR, Patel NB, Gibson CR, Samuels BC, Laurie SS, Otto C, Ferguson CR, Lee SM, PloutzSnyder R, Kramer LA, Mader TH. Association of long-duration spaceflight with anterior and posterior ocular structure changes in astronauts and their recovery. JAMA Ophthalmol. 2020. Advance publication online. doi: 10.1001/ jamaophthalmol.2020.0673 In this longitudinal prospective cohort study, the investigators evaluated the ocular ","PeriodicalId":19257,"journal":{"name":"Neuro-Ophthalmology","volume":"55 1","pages":"275 - 280"},"PeriodicalIF":0.8,"publicationDate":"2020-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90365855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuro-Ophthalmic Literature Review 神经眼科文献综述

IF 0.8

Neuro-Ophthalmology Pub Date : 2020-04-29 DOI: 10.1080/01658107.2020.1744930

D. Bellows, N. Chan, John J. Chen, Hui-Chen Cheng, P. Macintosh, J. N. Nij Bijvank, P. Jindahra, M. Vaphiades

{"title":"Neuro-Ophthalmic Literature Review","authors":"D. Bellows, N. Chan, John J. Chen, Hui-Chen Cheng, P. Macintosh, J. N. Nij Bijvank, P. Jindahra, M. Vaphiades","doi":"10.1080/01658107.2020.1744930","DOIUrl":"https://doi.org/10.1080/01658107.2020.1744930","url":null,"abstract":"Neuro-Ophthalmic Literature Review David A. Bellows, Noel C.Y. Chan, John J. Chen, Hui-Chen Cheng, Peter W. MacIntosh, Jenny A. Nij Bijvank, Panitha Jindahra, and Michael S. Vaphiades Finally, a targeted treatment for active thyroid eye disease! Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4): 341–352. doi:10.1056/NEJMoa1910434. Teprotumumab is an insulin-like growth factor I receptor (IGF-IR) inhibitor recently approved by the FDA for treatment of thyroid eye disease. In this phase 3 multicentre trial 41 patients with active thyroid eye disease were assigned to receive teprotumumab or placebo once every three weeks for 21 weeks. The primary outcome was a ≥ 2 mm reduction in proptosis at week 24. Secondary outcomes included; the overall response (defined as a ≥ 2 reduction in the Clinical Activity Score plus a ≥ 2 reduction in proptosis), a Clinical Activity Score of 0 or 1, the mean change in proptosis during the trial, a diplopia response and, finally, the mean change in overall score on quality of life measures. With respect to the primary outcome, 83% of patients receiving teprotumumab showed a ≥ 2 mm reduction in proptosis as compared to 10% of those receiving placebo. This response was seen early, at week six, in most patients, and increased throughout the trial. At week 24 the mean reduction in proptosis in the teprotumumab group was 3.32 mm. All secondary outcomes were also significantly better in the teprotumumab group. Orbital imaging was obtained in six patients in the teprotumumab group which showed a 35% reduction in mean extraocular muscle volume. Orbital fat volume was decreased by 40% or more in two patients. Most adverse events were of grade 1 or 2 and occurred in at least 5% of patients who received teprotumumab. Two patients suffered infusion reactions. One of these patients discontinued the trial. The second patient was able to remain in the study. This patient was premedicated and treated with a slower rate of infusion. Other adverse effects in the group receiving teprotumumab included two patients with mild hyperglycaemia and five patients who suffered hearing impairment which resolved in all cases and five patients had weight loss (one was intentional). Two patients suffered serious reactions which included pneumothorax and an infusion reaction.","PeriodicalId":19257,"journal":{"name":"Neuro-Ophthalmology","volume":"44 1","pages":"206 - 212"},"PeriodicalIF":0.8,"publicationDate":"2020-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81246739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Kline’s Neuro-Ophthalmology Review Manual Eighth Edition 克莱恩神经眼科学评论手册第八版

IF 0.8

Neuro-Ophthalmology Pub Date : 2020-03-03 DOI: 10.1080/01658107.2019.1692872

David A. Bellows

引用次数: 2

Neuro-Ophthalmic Literature Review 神经眼科文献综述

IF 0.8

Neuro-Ophthalmology Pub Date : 2020-02-26 DOI: 10.1080/01658107.2020.1717901

D. Bellows, N. Chan, John J. Chen, Hui-Chen Cheng, P. Macintosh, J. N. Nij Bijvank, M. Vaphiades

{"title":"Neuro-Ophthalmic Literature Review","authors":"D. Bellows, N. Chan, John J. Chen, Hui-Chen Cheng, P. Macintosh, J. N. Nij Bijvank, M. Vaphiades","doi":"10.1080/01658107.2020.1717901","DOIUrl":"https://doi.org/10.1080/01658107.2020.1717901","url":null,"abstract":"Neuro-Ophthalmic Literature Review David A. Bellows, Noel C.Y. Chan, John J. Chen, Hui-Chen Cheng, Peter W MacIntosh, Jenny A. Nij Bijvank, and Michael S. Vaphiades Smoking, among other factors, carries an increased risk of conversion from ocular to generalised myasthenia gravis. Apinyawasisuk S, Chongpison Y, Thitisaksakul C, Jariyakosol S. Factors affecting generalization of ocular myasthenia gravis in patients with positive acetylcholine receptor antibody. Am J Ophthalmol 2020;209:10–17. doi:10.1016/j.ajo.2019.09.019 The purpose of this retrospective study was to identify those factors that were associated with an increased or decreased risk of conversion from ocular myasthenia gravis to generalised myasthenia gravis. The authors reviewed the records of 71 patients who presented with ocular myasthenia, between July 2009 and December 2016, and had a positive test for acetylcholine receptor antibody. At the end of the study period, 35 patients remained purely ocular myasthenic and 36 patients converted to generalised myasthenia gravis. Factors associated with conversion to generalised myasthenia gravis, and their adjusted odds ratios, include female sex (4.02), smoking (6.13) and the presence of a thymic abnormality (4.13). Factors associated with a lower risk of conversion to generalised myasthenia gravis included treatment with immunosuppressive agents (0.47) and pyridostigmine (0.23). The age of onset of ocular myasthenia gravis and the presence of other autoimmune disorders were not found to increase or decrease the risk of conversion to generalised myasthenia gravis. David A. Bellows Artificial intelligence for disc swelling: Does it work? Ahn, JM, Kim S, Ahn K-S, Cho S-H, Kim US. Accuracy of machine learning for differentiation between optic neuropathies and pseudopapilledema. BMC Opthalmol 2019;19:178. doi:10.1186/ s12886-019-1184-0 Artificial intelligence has been a hot topic in the evaluation of various ophthalmic disorders such as glaucoma and diabetic retinopathy. In neurology, it has also been evaluated for predicting dementia at an early stage. It is not surprising that this technology will eventually be employed in the field of neuroophthalmology. This study tried to evaluate the efficacy of machine learning for differentiating optic neuropathies, pseudo-papilloedema, and normal controls using fundus photographs. Non-mydriatic fundus cameras were used to capture a total of 1369 images from the three groups, which include 295 images of optic neuropathies, 295 of pseudo-papilloedema and 779 normal control images. The optic neuropathies group comprised 177 cases of ischaemic optic neuropathy, 48 of optic neuritis, 17 of diabetic optic neuropathy, 22 of papilloedema, and 31 of disc swelling secondary to retinal disorders (such as central retinal vein occlusion). All subjects in the pseudo-papilloedema group had normal visual function for more than 1 year with normal optical coherence tomography (OCT) findings. The entire set of images ","PeriodicalId":19257,"journal":{"name":"Neuro-Ophthalmology","volume":"135 1","pages":"132 - 138"},"PeriodicalIF":0.8,"publicationDate":"2020-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86353471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuro-Ophthalmology Illustrated, 3rd Edition 神经眼科学插图，第三版

IF 0.8

Neuro-Ophthalmology Pub Date : 2020-01-31 DOI: 10.1080/01658107.2020.1714667

D. Bellows

{"title":"Neuro-Ophthalmology Illustrated, 3rd Edition","authors":"D. Bellows","doi":"10.1080/01658107.2020.1714667","DOIUrl":"https://doi.org/10.1080/01658107.2020.1714667","url":null,"abstract":"“Third time’s the charm!” That is the first line in Drs. Biousse and Newman’s preface to the third edition of Neuro-Ophthalmology Illustrated and I couldn’t agree more. These two world-renowned neuro-ophthalmologists have ushered this important work into the 21st century. This third edition will undoubtably secure its position as the “go to” reference for neurologists, ophthalmologists and physicians-in-training when challenged with a patient who has a neuro-ophthalmological disorder. Each chapter guides you through the steps in evaluating the patient’s symptoms using an abundance of high-quality illustrations, tables, charts and flowsheets. In addition, there is an invaluable compendium of 69 videos that can be rapidly accessed using a “QCode” on your smart phone. For example, there are fifteen videos just devoted to the evaluation of nystagmus! Neuro-Ophthalmology Illustrated has 21 chapters including the neuro-ophthalmological examination, optic neuropathies, diplopia, nystagmus, disorders of the eyelids and more. In addition, there is a highly detailed, fourteen page index which will quickly direct you to the information you seek. Unfortunately, we can’t all have Drs. Biousse and Newman at our side in the clinic to share their “pearls.” So, when you’re presented with a patient who has a challenging neuro-ophthalmological symptom, NeuroOphthalmology Illustrated is the next best thing.","PeriodicalId":19257,"journal":{"name":"Neuro-Ophthalmology","volume":"413 1","pages":"274 - 274"},"PeriodicalIF":0.8,"publicationDate":"2020-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86840405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0